Home > Healthcare > Drug Device Combination > Therapeutic Systems > Overactive Bladder Treatment Market

Overactive Bladder Treatment Market Trends

  • Report ID: GMI9699
  • Published Date: May 2024
  • Report Format: PDF

Overactive Bladder Treatment Market Trends

Advancements in the treatment of overactive bladder coupled with a growing demand for minimally invasive options are propelling market demand. Innovations such as neuromodulation, an electrical stimulator that uses electrical impulses to regulate bladder activity, and help relax bladder muscles, offer effective alternatives to traditional treatments. This therapy is designed to offer substantial symptom relief with fewer side effects and shorter recovery times, has captured significant attention, thereby fueling market demand.
 

  • For instance, in February 2024, Avation Medical, an innovative neuromodulation and digital health company introduced its Vivally System. Vivally is the first and only non-invasive, FDA-cleared, wearable neuromodulation system for home use that delivers closed-loop, autonomously adjusted electrical stimulation to treat patients with urge urinary incontinence and urinary urgency caused by overactive bladder syndrome. This launch marked a significant advancement in the non-invasive treatment options available for overactive bladder patients.
     

Therefore, ongoing research for the development of combined therapies and innovative approaches to enhance treatment effectiveness are few factors fostering the expansion of the market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global industry size for overactive bladder treatment was valued at USD 3.5 billion in 2023 and is anticipated to register 4.3% CAGR between 2024 and 2032 due to rising prevalence of overactive bladder and increasing research investments and activities.

The drug therapy segment in the overactive bladder treatment market held 48.9% revenue share in 2023 as drug therapies are widely prescribed due to their efficacy in managing overactive bladder symptoms and increasing regulatory support.

Asia Pacific market size is expected to record 4.7% CAGR between 2024 and 2032 due to the rising healthcare infrastructure development and increasing awareness about urinary disorders.

AbbVie Inc., Astellas Pharma Inc., Axonics, Inc., BlueWind Medical, Cipla Ltd., Endo International plc, Laborie, Lupin Ltd., Medtronic plc, Merck & Co., and Pfizer, Inc, among others.

Overactive Bladder Treatment Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 15
  • Tables & Figures: 264
  • Countries covered: 22
  • Pages: 130
 Download Free Sample